News Releases

When the facility opens in fall 2022, it will be the first proton therapy center in South Jersey and one of just 42 in the United States. This new, suburban community location provides patients added convenience of being nearer to home and loved ones while undergoing treatment and recovery.

The five-year award will fund three new melanoma research projects that translate fundamental laboratory discoveries made in the Perelman School of Medicine at the University of Pennsylvania and The Wistar Institute into new therapeutics to treat skins cancers.

The Institute for Regenerative Medicine at the University of Pennsylvania has awarded C. David Allis, PhD, an American molecular biologist, with the inaugural Elaine Redding Brinster Prize in Science or Medicine.

An analysis of nearly 200,000 patients who received mammograms between 2006 and 2015 across three U.S. health systems underscores the importance of understanding the heterogeneity of breast cancer risk factors for women of differing races, ages, and disease subtypes.

A popular class of diabetes medications called GLP-1R agonists (Trulicity and Rybelsus) may also protect against glaucoma in diabetic patients, according to a new study led by researchers in the Scheie Eye Institute at the University of Pennsylvania’s Perelman School of Medicine. The findings were published in the British Journal of Ophthalmology.

Exposure to neighborhood gun violence is associated with increased odds of mental health-related pediatric Emergency Department (ED) visits among children living within four to five blocks of a shooting, according to research by the Perelman School of Medicine at the University of Pennsylvania and Children’s Hospital of Philadelphia, published today in JAMA Pediatrics.

New “maps” of hundreds of thousands of cells related to inflammatory bowel disease shed greater light on their effects on intestinal tissues through a newly utilized imaging technique called “imaging mass cytometry.”

The National Institutes of Health (NIH) has selected Penn Medicine as one of 25 award recipients across 30 sites in the United States to serve as Impact of Genomic Variation on Function (IGVF) investigators, with the goal of better understanding how genetic differences impact how human genes function, and how these variations influence human health and disease.

New research shows that Multiple Sclerosis (MS) patients undergoing anti-CD20 (aCD20) treatment – which depletes the B cells that contribute to the MS attacks – are able to mount robust T-cell responses to the mRNA COVID-19 vaccines, despite having a muted antibody response to the vaccines.